EGFR and non-small cell lung carcinoma: EGFR-tyrosine kinase inhibitors (TKIs) such as gefitinib and erlotinib have been demonstrated to increase response rates, extend survival and improve quality of life as compared with standard platinum-based chemotherapy in patients with advanced NSCLC with activating EGFR mutation 3,4.